Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp. -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (954)	2/14/1998 4:22:00 PM
From: Pullin-GS	Respond to of 3576

I don't consider West leaving Geron bad news at all. He was only the founder of the company.....I guess that he had such high hopes for GERN succeeding that he just thought he would let someone else soak in the glory and receive the financial rewards. ;-) Now that Geron is a more established and publicly-traded company, he's apparently interested in moving on to something different. *Sigh*...Now he is off to spend another couple of mill of his money to get another company started so someone else can make it "more established". I wonder how much better MSFT, ORCL, or INTC would have done if the founders would have left in their infancies. Or let me present another possibility...he bailed before the feces hit the fan. Perhaps he was the insider selling his shares last month? Note the stock tanked from 13 1/4 to 12 1/4 within 24 hours of the news being released. I guess the market has spoken. I do expect GERN will (any smart company would at least) release some positive news soon in response to this....that is why I covered my short. The stock will recover some...in the short term. Good luck.

To: BulbaMan who wrote (954)	2/15/1998 11:00:00 PM
From: RJR	Read Replies (1) \| Respond to of 3576

RE: Departure of Founder and Key Executive Consider GERN's 10-Q November 14, 1997 wherein they stated as one of their risks: DEPENDENCE ON KEY PERSONNEL The Company is highly dependent on the principal members of its scientific and management staff, the loss of whose services might significantly delay or prevent the achievement of research, development or business objectives. ... The Company faces competition for qualified individuals from numerous pharmaceutical, biopharmaceutical and biotechnology companies, as well as academic and other research institutions. There can be no assurance that the Company will be able to attract and retain such individuals on acceptable terms and the failure to do so would have a material adverse effect on the Company. RJR